President and CEO of Seattle Genetics Inc (30-Year Financial, Insider Trades) Clay B Siegall (insider trades) sold 28,472 shares of SGEN on 06/08/2020 at an average price of $148.77 a share. The total sale was $4.2 million.
Seattle Genetics Inc is a biotechnology company. The company is focused on development and commercialization of targeted therapies for the treatment of cancer. Its products are ADCETRIS (brentuximab vedotin) US and ADCETRIS (brentuximab vedotin) Canada. Seattle Genetics Inc has a market cap of $27.13 billion; its shares were traded at around $156.70 with and P/S ratio of 27.62. GuruFocus has detected 2 severe warning signs with Seattle Genetics Inc. .
CEO Recent Trades:
- President and CEO Clay B Siegall sold 28,472 shares of SGEN stock on 06/08/2020 at the average price of $148.77. The price of the stock has increased by 5.33% since.
Directors and Officers Recent Trades:
- Director, 10% Owner Bros. Advisors Lp Baker sold 1,750,000 shares of SGEN stock on 05/15/2020 at the average price of $160. The price of the stock has decreased by 2.06% since.
- EVP, Commercial Charles R Romp sold 6,942 shares of SGEN stock on 05/12/2020 at the average price of $166. The price of the stock has decreased by 5.6% since.
For the complete insider trading history of SGEN, click here
.
